Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal?

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) stock is trading lower on Friday, despite no company-specific news, likely reacting to Natera Inc.'s (NASDAQ:NTRA) acquisition of cancer diagnostics firm Foresight Diagnostics for $275 million upfront and up to $175 million in additional earnouts tied to revenue- and reimbursement-based milestones."This acquisition reinforces Natera's position at the forefront of precision oncology," said Steve Chapman, chief executive officer of Natera.William Blair writes ...